A Phase 2 Study of Frontline Pembrolizumab in Follicular Lymphoma

Overview

Journal EJHaem

Specialty Hematology

Date 2024 Dec 18

PMID 39691260

Authors

Carrie Ho

Songli Zhu

Ted Gooley

Taranjit S Gujral

Ryan C Lynch

Christina Poh

Mazyar Shadman

Stephen D Smith

Yolanda Tseng

Ajay K Gopal

Affiliations

Soon will be listed here.

Abstract

Background: The tumor microenvironment (TME), including infiltrating T-cells, is thought to play a major role in the pathogenesis and prognosis of follicular lymphoma (FL) and may contribute to its widely varied disease course. We hypothesized that programmed death-1 inhibition may be most effective in untreated, immunocompetent FL patients. Thus, we developed a phase 2 study to evaluate the efficacy of pembrolizumab as the initial treatment for indolent B-cell lymphoma.

Methods: Adults with FL or marginal zone lymphoma and an indication for treatment were eligible. Patients received pembrolizumab 200 mg IV in 21-day cycles for up to 18 cycles, until progression or unacceptable toxicity. Early response assessment was obtained after cycle 3 with computed tomography (CT), and a fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET-CT) was obtained after cycle 6 to determine candidacy for continuation in the study. Immunosecretome profiling was performed at baseline and on cycle 2 day 1.

Results: Nine patients with FL were enrolled between February 2019 and April 2021, including eight (89%) with advanced stage, seven (78%) with intermediate/high Follicular Lymphoma International Prognostic Index, and six (67%) with high-tumor burden by Groupe d'Etude des Lymphomes Folliculaires. The best overall response rate by FDG PET-CT was 33% (three partial metabolic responses). Three patients (33%) had stable disease, and three (33%) had progressive disease (including one patient who only had a follow-up CT). By CT four (44%) experienced a reduction in target lesions, but all were less than partial responses. Grade 3 or higher immune-related adverse events (IRAEs) were seen in two (22%) patients, both with transaminitis and one of whom had concurrent hypophysitis. Another patient had grade 1 pneumonitis, requiring treatment with steroids. No associations between the immunosecretome profile and clinical outcomes could be detected.

Conclusion: Frontline pembrolizumab for FL is associated with limited responses and a clinically significant rate of IRAEs. Alternative strategies for targeting the TME in FL should be explored.

References

Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A . High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009; 27(9):1470-6. DOI: 10.1200/JCO.2008.18.0513. View

Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. DOI: 10.1016/0197-2456(89)90015-9. View

Whiteaker J, Zhao L, Schoenherr R, Huang D, Lundeen R, Voytovich U . A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials. Front Oncol. 2023; 13:1168710. PMC: 10185886. DOI: 10.3389/fonc.2023.1168710. View

Ho C, Gopal A, Till B, Shadman M, Lynch R, Cowan A . Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up. Clin Lymphoma Myeloma Leuk. 2023; 24(2):e33-e39.e1. PMC: 10841534. DOI: 10.1016/j.clml.2023.10.002. View

Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y . Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Cancer Res. 2018; 78(17):5011-5022. DOI: 10.1158/0008-5472.CAN-18-0118. View

Morad G, Helmink B, Sharma P, Wargo J . Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184(21):5309-5337. PMC: 8767569. DOI: 10.1016/j.cell.2021.09.020. View

Lynch R, Ujjani C, Poh C, Warren E, Smith S, Shadman M . Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood. 2023; 141(21):2576-2586. PMC: 10273164. DOI: 10.1182/blood.2022019254. View

Chennamadhavuni A, Abushahin L, Jin N, Presley C, Manne A . Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Front Immunol. 2022; 13:779691. PMC: 9086893. DOI: 10.3389/fimmu.2022.779691. View

Chan M, Kang Y, Osborne S, Zager M, Gujral T . A kinase to cytokine explorer to identify molecular regulators and potential therapeutic opportunities. Elife. 2024; 12. PMC: 10945549. DOI: 10.7554/eLife.91472. View

10.

Chan M, Vijay S, McNevin J, McElrath M, Holland E, Gujral T . Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release. Mol Syst Biol. 2021; 17(9):e10426. PMC: 8420181. DOI: 10.15252/msb.202110426. View

11.

Han G, Deng Q, Marques-Piubelli M, Dai E, Dang M, Ma M . Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov. 2022; 3(5):428-443. PMC: 9894575. DOI: 10.1158/2643-3230.BCD-21-0075. View

12.

Les I, Martinez M, Perez-Francisco I, Cabero M, Teijeira L, Arrazubi V . Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers (Basel). 2023; 15(5). PMC: 10000735. DOI: 10.3390/cancers15051629. View

13.

Lesokhin A, Ansell S, Armand P, Scott E, Halwani A, Gutierrez M . Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016; 34(23):2698-704. PMC: 5019749. DOI: 10.1200/JCO.2015.65.9789. View

14.

Kang D, Park C, Chung C, Oh I, Kim Y, Park D . Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors. Immune Netw. 2020; 20(3):e27. PMC: 7327149. DOI: 10.4110/in.2020.20.e27. View

15.

Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A . Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers. 2010; 29(1):47-53. PMC: 3835488. DOI: 10.3233/DMA-2010-0725. View

16.

Laurent C, Dietrich S, Tarte K . Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm. Blood. 2023; 143(12):1080-1090. DOI: 10.1182/blood.2023021000. View

17.

Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-69. DOI: 10.1056/NEJMoa041869. View

18.

Ramchandren R, Domingo-Domenech E, Rueda A, Trneny M, Feldman T, Lee H . Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol. 2019; 37(23):1997-2007. PMC: 6688776. DOI: 10.1200/JCO.19.00315. View

19.

Morschhauser F, Fowler N, Feugier P, Bouabdallah R, Tilly H, Palomba M . Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med. 2018; 379(10):934-947. PMC: 11003525. DOI: 10.1056/NEJMoa1805104. View

20.

Gravelle P, Burroni B, Pericart S, Rossi C, Bezombes C, Tosolini M . Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget. 2017; 8(27):44960-44975. PMC: 5546533. DOI: 10.18632/oncotarget.16680. View